Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Foghorn Therapeutics (FHTX) Liabilities and Shareholders Equity (2020 - 2025)

Foghorn Therapeutics (FHTX) has 6 years of Liabilities and Shareholders Equity data on record, last reported at $198.1 million in Q4 2025.

  • For Q4 2025, Liabilities and Shareholders Equity fell 30.24% year-over-year to $198.1 million; the TTM value through Dec 2025 reached $888.0 million, down 24.49%, while the annual FY2025 figure was $198.1 million, 30.24% down from the prior year.
  • Liabilities and Shareholders Equity reached $198.1 million in Q4 2025 per FHTX's latest filing, down from $205.0 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $519.8 million in Q4 2021 and bottomed at $186.1 million in Q3 2021.
  • Average Liabilities and Shareholders Equity over 5 years is $315.2 million, with a median of $297.1 million recorded in 2023.
  • Peak YoY movement for Liabilities and Shareholders Equity: skyrocketed 133.21% in 2022, then crashed 33.53% in 2025.
  • A 5-year view of Liabilities and Shareholders Equity shows it stood at $519.8 million in 2021, then dropped by 22.1% to $404.9 million in 2022, then fell by 29.38% to $285.9 million in 2023, then decreased by 0.68% to $284.0 million in 2024, then tumbled by 30.24% to $198.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Liabilities and Shareholders Equity were $198.1 million in Q4 2025, $205.0 million in Q3 2025, and $226.2 million in Q2 2025.